{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:08:43Z","timestamp":1790240923864,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T00:00:00Z","timestamp":1714694400000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006302","name":"Universidad de Alcal\u00e1","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006302","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.heliyon.2024.e30742","type":"journal-article","created":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T02:49:55Z","timestamp":1715050195000},"page":"e30742","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of fidaxomicin, metronidazole and vancomycin for initial episode and recurrence of Clostridioides difficile infection - An observational cohort study"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2838-7270","authenticated-orcid":false,"given":"Marcos","family":"Hernando-Gozalo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3745-6661","authenticated-orcid":false,"given":"Carlos","family":"Rescalvo-Casas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9360-7159","authenticated-orcid":false,"given":"Laura","family":"Seijas-Pereda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Cuadros-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00f3n","family":"P\u00e9rez-Tanoira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e30742_bib1","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s10096-019-03539-6","article-title":"Clostridium difficile infection: review","volume":"38","author":"Czepiel","year":"2019","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e30742_bib2","doi-asserted-by":"crossref","DOI":"10.4081\/idr.2011.2331","article-title":"Diagnosis of Clostridium difficile infection: comparison of four methods on specimens collected in Cary-Blair transport medium and tcdB PCR on fresh versus frozen samples","volume":"3","author":"Brown","year":"2011","journal-title":"Infect. Dis. Rep."},{"key":"10.1016\/j.heliyon.2024.e30742_bib3","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.eimc.2015.09.004","article-title":"Diagn\u00f3stico microbiol\u00f3gico de la infecci\u00f3n por Clostridium difficile","volume":"34","author":"Alcal\u00e1-Hern\u00e1ndez","year":"2016","journal-title":"Enferm. Infecc. Microbiol. Cl\u00edn."},{"key":"10.1016\/j.heliyon.2024.e30742_bib4","unstructured":"ECDC, European Centre for Disease Prevention and Control. Healthcare-associated Infections: Clostridium difficile Infections, Stockholm, 2018."},{"key":"10.1016\/j.heliyon.2024.e30742_bib5","unstructured":"J. Mensa Pueyo, A. Soriano Viladomiu, E. Lopez Sune, Y. Zboromyrska, P. Llinanres Mondejar, P. Barberan Lopez, Guia de terapeutica antimicrobiana 2023, Antares, Barcelona, 2023."},{"issue":"Suppl 2","key":"10.1016\/j.heliyon.2024.e30742_bib6","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.cmi.2021.09.038","article-title":"Guideline Committee of the European study group on Clostridioides difficile, European Society of clinical Microbiology and infectious diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults","volume":"27","author":"van Prehn","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.heliyon.2024.e30742_bib7","doi-asserted-by":"crossref","first-page":"e1029","DOI":"10.1093\/cid\/ciab549","article-title":"Clinical practice guideline by the infectious diseases Society of America (IDSA) and Society for Healthcare epidemiology of America (SHEA): 2021 Focused update guidelines on Management of Clostridioides difficile infection in adults","volume":"73","author":"Johnson","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e30742_bib8","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s15010-022-01778-y","article-title":"Non-inferiority of metronidazole to vancomycin in the treatment of first episode non-severe Clostridioides difficile infection: a single center retrospective cohort study","volume":"50","author":"Najjar-Debbiny","year":"2022","journal-title":"Infection"},{"key":"10.1016\/j.heliyon.2024.e30742_bib9","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00228-022-03376-1","article-title":"Real-world comparison of fidaxomicin versus vancomycin or metronidazole in the treatment of Clostridium difficile infection: a systematic review and meta-analysis","volume":"78","author":"Dai","year":"2022","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e30742_bib10","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.jiac.2018.08.003","article-title":"Oral vancomycin versus metronidazole for the treatment of Clostridioides difficile infection: meta-analysis of randomized controlled trials","volume":"24","author":"Igarashi","year":"2018","journal-title":"J. Infect. Chemother."},{"key":"10.1016\/j.heliyon.2024.e30742_bib11","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ijid.2020.11.004","article-title":"Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection \u2014 an observational cohort study","volume":"103","author":"Polivkova","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e30742_bib12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/jac\/dkac404","article-title":"Management of Clostridioides difficile infection in adults and challenges in clinical practice: review and comparison of current IDSA\/SHEA, ESCMID and ASID guidelines","volume":"78","author":"Bishop","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.heliyon.2024.e30742_bib13","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jiac.2019.07.005","article-title":"Fidaxomicin compared with vancomycin and metronidazole for the treatment of Clostridioides (Clostridium) difficile infection: a network meta-analysis","volume":"26","author":"Okumura","year":"2020","journal-title":"J. Infect. Chemother."},{"key":"10.1016\/j.heliyon.2024.e30742_bib14","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/jac\/dkz513","article-title":"Constitutive expression of the cryptic vanGCd operon promotes vancomycin resistance in Clostridioides difficile clinical isolates","volume":"75","author":"Shen","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.heliyon.2024.e30742_bib15","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1093\/jac\/dkad194","article-title":"In vivo emergence of a still uncommon resistance to fidaxomicin in the urgent antimicrobial resistance threat Clostridioides difficile","volume":"78","author":"Marchandin","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.heliyon.2024.e30742_bib16","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s13756-020-00815-5","article-title":"Antimicrobial resistance in Clostridioides (Clostridium) difficile derived from humans: a systematic review and meta-analysis","volume":"9","author":"Sholeh","year":"2020","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"10.1016\/j.heliyon.2024.e30742_bib17","first-page":"1","article-title":"Clostridioides difficile resistance to antibiotics, including post-COVID-19 data","author":"Boyanova","year":"2023","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.heliyon.2024.e30742_bib18","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jinf.2018.09.013","article-title":"PCR cycle threshold to assess a diagnostic stewardship intervention for C. difficile testing","volume":"78","author":"Madden","year":"2019","journal-title":"J. Infect."},{"key":"10.1016\/j.heliyon.2024.e30742_bib19","series-title":"PROTOCOLO GENERAL DE VIGILANCIA Y CONTROL DE MICROORGANISMOS MULTIRRESISTENTES O DE ESPECIAL RELEVANCIA CL\u00cdNICO-Epidemiol\u00f3gica (Protocolo-MMR)","year":"2016"},{"key":"10.1016\/j.heliyon.2024.e30742_bib20","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlad033","article-title":"Role of previous systemic antibiotic therapy on the probability of recurrence after an initial episode of Clostridioides difficile infection treated with vancomycin","volume":"5","author":"Merchante","year":"2023","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.heliyon.2024.e30742_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2023.1323257","article-title":"Characterization of community-acquired Clostridioides difficile strains in Israel, 2020-2022","volume":"14","author":"Schwartz","year":"2023","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.heliyon.2024.e30742_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e22053","article-title":"Vancomycin vs metronidazole use for the treatment of Clostridioides difficile infection in a tertiary care hospital in Saudi Arabia","volume":"9","author":"Alhameed","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.heliyon.2024.e30742_bib24","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jhin.2023.02.008","article-title":"A decade of Clostridioides difficile infection: a constant challenge to maintain the status quo","volume":"135","author":"Skally","year":"2023","journal-title":"J. Hosp. Infect."},{"key":"10.1016\/j.heliyon.2024.e30742_bib25","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1111\/acem.14600","article-title":"Oral fidaxomicin versus vancomycin for Clostridioides difficile infection","volume":"29","author":"Long","year":"2022","journal-title":"Acad. Emerg. Med."},{"key":"10.1016\/j.heliyon.2024.e30742_bib26","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.jiac.2022.08.008","article-title":"Oral fidaxomicin versus vancomycin for the treatment of Clostridioides difficile infection: a systematic review and meta-analysis of randomized controlled trials","volume":"28","author":"Tashiro","year":"2022","journal-title":"J. Infect. Chemother."},{"key":"10.1016\/j.heliyon.2024.e30742_bib27","doi-asserted-by":"crossref","first-page":"S162","DOI":"10.1093\/cid\/cis453","article-title":"Fidaxomicin inhibits Spore production in Clostridium difficile","volume":"55","author":"Babakhani","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e30742_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijmm.2021.151507","article-title":"Molecular epidemiology and antimicrobial resistance of Clostridioides difficile in Germany, 2014\u20132019","volume":"311","author":"Abdrabou","year":"2021","journal-title":"International Journal of Medical Microbiology"},{"key":"10.1016\/j.heliyon.2024.e30742_bib29","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00349-23","article-title":"A US-based national surveillance study for the susceptibility and epidemiology of Clostridioides difficile isolates with special reference to ridinilazole: 2020\u20132021","author":"Snydman","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.heliyon.2024.e30742_bib30","doi-asserted-by":"crossref","DOI":"10.1002\/mbo3.945","article-title":"Antimicrobial resistance: a multifaceted problem with multipronged solutions","volume":"8","author":"Gil\u2010Gil","year":"2019","journal-title":"Microbiologyopen"},{"key":"10.1016\/j.heliyon.2024.e30742_bib31","doi-asserted-by":"crossref","first-page":"7210","DOI":"10.3748\/wjg.v27.i42.7210","article-title":"Frontiers in antibiotic alternatives for Clostridioides difficile infection","volume":"27","author":"Phanchana","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.heliyon.2024.e30742_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199810","article-title":"Enhanced preservation of the human intestinal microbiota by ridinilazole, a novel Clostridium difficile-targeting antibacterial, compared to vancomycin","volume":"13","author":"Thorpe","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2024.e30742_bib33","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1473-3099(17)30235-9","article-title":"Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study","volume":"17","author":"Vickers","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e30742_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.mimet.2020.105974","article-title":"Molecular epidemiology of predominant and emerging Clostridioides difficile ribotypes","volume":"175","author":"Mart\u00ednez-Mel\u00e9ndez","year":"2020","journal-title":"J. Microbiol. Methods"},{"key":"10.1016\/j.heliyon.2024.e30742_bib35","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/cid\/civ254","article-title":"Clostridium difficile ribotype 027: Relationship to age, Detectability of toxins A or B in stool with rapid testing, severe infection, and mortality","volume":"61","author":"Rao","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e30742_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.anaerobe.2021.102440","article-title":"Comparative clinical outcomes evaluation of hospitalized patients infected with Clostridioides difficile ribotype 106 vs. other toxigenic strains","volume":"72","author":"Almutairi","year":"2021","journal-title":"Anaerobe"},{"key":"10.1016\/j.heliyon.2024.e30742_bib37","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/cid\/ciy302","article-title":"Patient and strain characteristics associated with Clostridium difficile Transmission and Adverse outcomes","volume":"67","author":"Martin","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e30742_bib38","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/cix1085","article-title":"Clinical practice guidelines for Clostridium difficile infection in adults and Children: 2017 update by the infectious diseases Society of America (IDSA) and Society for Healthcare epidemiology of America (SHEA)","volume":"66","author":"McDonald","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e30742_bib39","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1086\/651706","article-title":"Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare epidemiology of America (SHEA) and the infectious diseases Society of America (IDSA)","volume":"31","author":"Cohen","year":"2010","journal-title":"Infect. Control Hosp. Epidemiol."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024067732?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024067732?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:42:11Z","timestamp":1790239331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024067732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S2405844024067732"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e30742","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of fidaxomicin, metronidazole and vancomycin for initial episode and recurrence of Clostridioides difficile infection - An observational cohort study","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e30742","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e30742"}}